PAD: R3 Vascular reports ‘successful initiation’ of first-in-human study of bioresorbable sirolimus-eluting scaffold

Medical device developer R3 Vascular has reported the “successful initiation” of a first-in-human clinical study evaluating the technical and clinical performance of its Magnitude bioresorbable sirolimus-eluting scaffold (BRS) in patients with critical limb ischemia (CLI) due to occlusive below-the-knee (BTK)…

